[go: up one dir, main page]

ES2135416T3 - Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv. - Google Patents

Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.

Info

Publication number
ES2135416T3
ES2135416T3 ES92922090T ES92922090T ES2135416T3 ES 2135416 T3 ES2135416 T3 ES 2135416T3 ES 92922090 T ES92922090 T ES 92922090T ES 92922090 T ES92922090 T ES 92922090T ES 2135416 T3 ES2135416 T3 ES 2135416T3
Authority
ES
Spain
Prior art keywords
piridopiridazinones
compounds
piridazinons
pde
acil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922090T
Other languages
English (en)
Inventor
Robert Stephen Wilhelm
Bradley Earl Loe
Bruce Henry Devens
Robert Alvarez
Michael Grant Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2135416T3 publication Critical patent/ES2135416T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE HA DESCUBIERTO QUE LOS COMPUESTOS DE BENZO O PIRIDOPIRIDAZINONAS Y PIRIDAZINTIONAS DE LA FORMULA (I) EN LA QUE: X E Y SON NITROGENO O CARBONO, SIEMPRE Y CUANDO AL MENOS UNO DE ELLOS SEA CARBONO Y Z ES OXIGENO O AZUFRE; R1 ES HIDROGENO, ALKILO INFERIOR, ARILO, HETEROARILO O ALKILENO INFERIOR HETEROCICLICO; R2, R3, R4, R5 Y R6 SE SELECCIONAN INDEPENDIENTEMENTE DEL HIDROGENO, ALKILO INFERIOR, HALO, CARBOXI, ALCOXICARBONILO, CARBAMILO, ACILO, HALURO DE ACILO, TIOMETILO, TRIFLUOMETILO, CIANO O NITRO; O UN ESTER, ETER O SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, SON UTILES COMO AGENTES ANTIINFLAMATORIOS, ANTIASMATICOS, INMUNOSUPERSORES, ANTI RECHAZO A LOS ALOINJERTOS, ANTI RECHAZO A LOS INJERTOS FRENTE A HUESPEDES, ENFERMEDADES AUTOINMUNES O ANALGESICOS.
ES92922090T 1991-10-09 1992-10-08 Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv. Expired - Lifetime ES2135416T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77567991A 1991-10-09 1991-10-09

Publications (1)

Publication Number Publication Date
ES2135416T3 true ES2135416T3 (es) 1999-11-01

Family

ID=25105161

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92922090T Expired - Lifetime ES2135416T3 (es) 1991-10-09 1992-10-08 Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.
ES09201998A Expired - Fee Related ES2105920B1 (es) 1991-10-09 1992-10-08 Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09201998A Expired - Fee Related ES2105920B1 (es) 1991-10-09 1992-10-08 Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.

Country Status (20)

Country Link
EP (1) EP0612321B1 (es)
JP (1) JP3245165B2 (es)
KR (1) KR100263494B1 (es)
AT (1) ATE183745T1 (es)
AU (1) AU670544B2 (es)
CA (1) CA2117059C (es)
DE (1) DE69229874T2 (es)
DK (1) DK0612321T3 (es)
ES (2) ES2135416T3 (es)
FI (1) FI108229B (es)
GR (1) GR3030969T3 (es)
HU (2) HUT66969A (es)
IL (1) IL103388A (es)
MX (1) MX9205794A (es)
NO (1) NO302888B1 (es)
NZ (1) NZ244660A (es)
PT (1) PT100938B (es)
TW (1) TW365606B (es)
WO (1) WO1993007146A1 (es)
ZA (1) ZA927755B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200689D0 (en) * 1992-01-14 1992-03-11 Rhone Poulenc Agriculture New compositions of matter
GB9314412D0 (en) * 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
CA2197984A1 (en) * 1994-08-29 1996-03-07 Kazuhisa Takayama Novel naphthyridine derivatives and pharmaceutical compositions thereof
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
IL136359A (en) 1997-12-15 2003-03-12 Byk Gulden Lomberg Chem Fab Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same
EP0934933A1 (en) * 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
ATE320800T1 (de) 1999-08-21 2006-04-15 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
WO2002064584A1 (en) * 2001-02-15 2002-08-22 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors
US7022696B2 (en) 2001-04-25 2006-04-04 Altana Pharma Ag Piperazino-derivatives and their use as PDE4 inhibitor
CN1503792A (zh) 2001-04-25 2004-06-09 ��̹��ҽҩ��˾ 新的酞嗪酮
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
DE60313472T2 (de) 2002-08-10 2008-01-24 Nycomed Gmbh Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren
CA2494643A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1624893A2 (en) 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
CA2554797C (en) 2004-02-04 2012-09-04 Altana Pharma Ag 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL383550A1 (pl) * 2007-10-15 2009-04-27 Uniwersytet Łódzki Nowe pochodne benzeno- i pirydopirydazynonów
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2828346C (en) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
JP6857606B2 (ja) * 2015-03-05 2021-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン
JP6837052B2 (ja) * 2016-03-09 2021-03-03 日本曹達株式会社 ピリジン化合物およびその用途
EP3693369A3 (en) 2016-04-15 2020-09-09 AbbVie Inc. Bromodomain inhibitors
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
FR3105254B1 (fr) 2019-12-19 2022-08-12 Syctom Lagence Metropolitaine Des Dechets Menagers Installation et procédé de gazéification hydrothermale de biomasse

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2805344B2 (ja) * 1989-07-11 1998-09-30 昭和電工株式会社 オレフィン重合触媒の製造方法およびオレフィンの重合方法
JP3120857B2 (ja) * 1990-02-19 2000-12-25 中外製薬株式会社 新規な縮合複素環化合物とこれを用いた抗喘息剤

Also Published As

Publication number Publication date
PT100938A (pt) 1993-10-29
AU2781592A (en) 1993-05-03
WO1993007146A1 (en) 1993-04-15
IL103388A (en) 1997-09-30
FI941567A0 (fi) 1994-04-06
ES2105920A1 (es) 1997-10-16
ES2105920B1 (es) 1998-07-01
EP0612321A1 (en) 1994-08-31
ZA927755B (en) 1994-04-08
NO941210D0 (no) 1994-04-05
DK0612321T3 (da) 1999-12-13
FI108229B (fi) 2001-12-14
HUT66969A (en) 1995-01-30
NO302888B1 (no) 1998-05-04
NZ244660A (en) 1995-05-26
CA2117059C (en) 2003-05-20
GR3030969T3 (en) 1999-11-30
NO941210L (no) 1994-04-05
DE69229874T2 (de) 1999-12-09
EP0612321B1 (en) 1999-08-25
CA2117059A1 (en) 1993-04-15
HU9400949D0 (en) 1994-06-28
IL103388A0 (en) 1993-03-15
AU670544B2 (en) 1996-07-25
JP3245165B2 (ja) 2002-01-07
HU210814A9 (en) 1995-08-28
KR940702868A (ko) 1994-09-17
PT100938B (pt) 1999-10-29
TW365606B (en) 1999-08-01
JPH07500321A (ja) 1995-01-12
DE69229874D1 (de) 1999-09-30
ATE183745T1 (de) 1999-09-15
FI941567L (fi) 1994-04-06
MX9205794A (es) 1993-04-01
KR100263494B1 (ko) 2000-08-01

Similar Documents

Publication Publication Date Title
ES2135416T3 (es) Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv.
ATE162527T1 (de) Piperazinderivate als 5-ht1a antagonisten.
ES2036551T3 (es) Compuestos heterociclicos.
ES469952A1 (es) Un procedimiento para la preparacion de aminoalquiltiofenos
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
ES2067500T3 (es) 1-indolilalquil-4-(piridinil-sustituidas)piperazinas.
CO4790091A1 (es) Derivados sustituidos de acido 3-sulfonil-propionico
MY106980A (en) Heterocyclic compounds
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES463126A1 (es) Procedimiento para preparar esteres de anilicos de acidos 4,5-dicloro-imidazol-1-carboxilicos.
ES2065133T3 (es) Derivados de piperazina.
ES468119A1 (es) Un procedimiento para la preparacion de triazinas
ES8500902A1 (es) Un procedimiento para la preparacion de un derivado del indol.
DE69522703D1 (de) Aminotetrazol-derivate verwendbar als stickstoff-oxid-synthase inhibitoren
ES8100280A1 (es) Un procedimiento para la preparacion de derivados de benzoxazol
MY131381A (en) Piperazine derivatives suitable for use as pharmaceuticals, in particular as 5-ht1a receptor binding agents.
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
ES466143A1 (es) Un procedimiento de preparacion de nuevas imidazoquinoleinas
ES474155A1 (es) Un procedimiento para la preparacion de nuevos derivados de aminoalquilfurano
ES8203855A1 (es) Un procedimiento para la preparacion de derivados de imida- lol.
ES8400440A1 (es) "procedimiento para preparar nuevas triazoloquinazolonas".
AR012553A1 (es) Una composicion que posee propiedades antivirales, en base a 7h-benz (de) antracenos y las composiciones farmaceuticas que los contienen conjuntamentecon derivados de la benzantrona
IT1216522B (it) Derivati alchiltiobenzimidazolici attivi farmacologicamente eprocedimento per la loro preparazione.
ES463162A1 (es) Procedimiento para la obtencion de derivados de 4,5-dicloro-imidazol.
ES469203A1 (es) Un procedimiento para la preparacion de benzo (c) quinolei- nas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612321

Country of ref document: ES